Compare the product, the provider, and the price at the listed dose. Starting offers and maintenance prices stay side by side.
Every cash quote was checked on or after . Individual offer checks appear with their price conditions. Sources & methodology
Search by medication, provider or treatment goal. Examples follow.
CMS acquisition costs are what pharmacies pay, not patient prices. These are the lowest presentation rates in the latest complete release we checked, shown alphabetically by dosage form. Different concentrations and doses mean a lower unit price does not establish a lower treatment cost.
Patient copays, negotiated drug prices, and manufacturer list prices answer different questions. Check the covered product, eligibility, and published dates.
Patient copay
For eligible Part D enrollees using a covered product for weight management, with prior authorization. Bridge operates outside the Part D benefit. Its copay does not count toward Part D out-of-pocket spending, and the Part D deductible does not apply.
Published effective dates: to
Check Medicare eligibility and coverageInjection and tablets
per 28- or 30-day fill
Published price snapshots, grouped by brand and country. Reporting years, doses, and price definitions differ, so these records cannot establish today’s price gap.
The ingredient index tracks pharmacy acquisition costs over windows up to 9 days long, not patient cash prices or just the presentation listed above. Each NDC starts at 100; we average its percentage change with the same NDCs at every point, so per-tablet and per-mL dollar prices are never averaged together. Incomplete days are omitted. “Flat” means a change smaller than 0.5%. Insufficient or truncated history shows no index.
Source: NADAC (Data.Medicaid.gov)
KwikPen only. Single-dose pens and vials are excluded.
per 28- or 30-day fill
Tablets
per 28- or 30-day fill
Negotiated drug price
CMS maximum fair prices for these exact packages, for eligible Medicare coverage. These are drug prices, not patient copays. Your out-of-pocket cost depends on your plan and coverage.
Scheduled: to
Manufacturer list price
Announced US wholesale acquisition cost for Wegovy injection and tablets, Ozempic injection and Rybelsus tablets. This is a list price, not a patient quote. Novo says the change does not affect its direct-to-patient self-pay prices.
Scheduled:
Products named in Novo's February 2026 announcement; see source for doses.
References include manufacturer list prices and reported pharmacy prices, not a single comparable measure of patient cost. Sources span different years; each amount links to its original record. Confirm current local pricing and coverage with a licensed pharmacy.
58 offers · US self-pay · 17 maintenance quotes
This order ignores commission. Partner links may earn us a referral fee.
Orforglipron · Manufacturer direct
$149 per 30 days at this quoted rate
Checked
self-pay cash, lowest dose; ~$25/mo with commercial coverage
Maintenance terms: Self-Pay Journey price for 14.5 mg and 17.2 mg with a refill within 45 days; regular price $349. Eligibility, additional taxes and fees may apply.
The first oral small-molecule GLP-1 pill for weight loss; FDA-approved April 2026. LillyDirect self-pay ladder: $149 (0.8 mg), $199 (2.5 mg), $299 (5.5 and 9 mg), $299 (14.5 and 17.2 mg with a 45-day refill, else $349); the 2.5 mg and 5.5 mg doses are temporarily $149 and $199 through Dec 31, 2026.
Confirm the prescribed dose, supply length, membership or consultation fees, and refill conditions with the provider. A listed offer does not confirm eligibility or stock.
Read the advertised-price sourceSemaglutide · Manufacturer direct
$149 per 30 days at this quoted rate
Checked
self-pay, 1.5 mg starting dose
Maintenance terms: 30 tablets per bottle. The 4 mg strength costs $199 per 30-day fill; 9 mg costs $299.
A prescription is required. The 1.5 mg initiation dose costs $149 for 30 tablets. Self-pay purchases are processed outside insurance and do not count toward deductibles or out-of-pocket limits. Ozempic tablet prices are separate from Wegovy tablet prices.
Confirm the prescribed dose, supply length, membership or consultation fees, and refill conditions with the provider. A listed offer does not confirm eligibility or stock.
Read the advertised-price sourceSemaglutide · Manufacturer direct
$149 per 30 days at this quoted rate
Checked
self-pay cash, lowest dose (1.5 mg)
Maintenance terms: $149 (1.5 mg), $199 (4 mg), $299 (9 mg and 25 mg).
$149/mo for 1.5 mg; $199 for 4 mg (the 4 mg $149 promo ended Aug 31, 2026); $299 for 9 mg and 25 mg.
Confirm the prescribed dose, supply length, membership or consultation fees, and refill conditions with the provider. A listed offer does not confirm eligibility or stock.
Read the advertised-price sourceSemaglutide · Retail cash / discount
$149 per 30 days at this quoted rate
Checked
by dose; Novo Nordisk's self-pay price through a GoodRx coupon
Third-party report
The same oral semaglutide and prices as the NovoCare offer: $149 (1.5 mg), $199 (4 mg), $299 (9 mg and 25 mg), per Novo Nordisk's published self-pay ladder. FDA-approved product.
Confirm the prescribed dose, supply length, membership or consultation fees, and refill conditions with the provider. A listed offer does not confirm eligibility or stock.
Read the advertised-price sourceSemaglutide · Manufacturer direct
≈ $213.21 per 30 days at this quoted rate
Offer through
Checked
first two monthly fills at 0.25 or 0.5 mg for new patients, prescribed by Dec 31, 2026
Maintenance terms: One price for every standard dose (0.25-2.4 mg).
After the introductory offer, standard doses cost $349 per box of four weekly pens. Wegovy HD (7.2 mg) is $399. Eligibility and restrictions apply.
Confirm the prescribed dose, supply length, membership or consultation fees, and refill conditions with the provider. A listed offer does not confirm eligibility or stock.
Read the advertised-price sourceDulaglutide · Manufacturer direct
≈ $416.79 per 30 days at this quoted rate
Checked
self-pay, four weekly pens; published starting rate at each dose
Maintenance terms: The same starting rate is published for 0.75, 1.5, 3 and 4.5 mg. Taxes and additional fees may apply.
The self-pay program requires a prescription for an approved use, age 18+, and US or Puerto Rico residence. Purchases cannot be submitted to insurance or counted toward deductibles or out-of-pocket limits. Four once-weekly pens cover 28 days.
Confirm the prescribed dose, supply length, membership or consultation fees, and refill conditions with the provider. A listed offer does not confirm eligibility or stock.
Read the advertised-price sourceSemaglutide · Manufacturer direct
≈ $427.50 per 30 days at this quoted rate
Checked
self-pay cash, 7.2 mg dose
One box contains four weekly pens. This is the HD maintenance dose, not a treatment starting dose. The $199 introduction applies only to 0.25 and 0.5 mg standard Wegovy. Prescription, eligibility and restrictions apply.
Confirm the prescribed dose, supply length, membership or consultation fees, and refill conditions with the provider. A listed offer does not confirm eligibility or stock.
Read the advertised-price sourceTirzepatide · Manufacturer direct
≈ $320.36 per 30 days at this quoted rate
Checked
self-pay cash, by dose ($299 / $399 / $449)
Maintenance terms: Self Pay Journey price for 7.5-15 mg with a refill within 45 days; otherwise $499 (7.5 mg) or $699 (10-15 mg). Pen needles cost extra.
Four weekly doses per pen; pen needles must be purchased separately. $299 at 2.5 mg, $399 at 5 mg, and $449 at higher doses under the Self Pay Journey offer with a refill within 45 days.
Confirm the prescribed dose, supply length, membership or consultation fees, and refill conditions with the provider. A listed offer does not confirm eligibility or stock.
Read the advertised-price sourceTirzepatide · Manufacturer direct
≈ $320.36 per 30 days at this quoted rate
Checked
self-pay cash, starting dose
Maintenance terms: Self Pay Journey price for 7.5-15 mg with a refill within 45 days; otherwise $499 (7.5 mg) or $699 (10-15 mg).
Cash-only via LillyDirect; not billable to insurance. Needles and syringes cost extra.
Confirm the prescribed dose, supply length, membership or consultation fees, and refill conditions with the provider. A listed offer does not confirm eligibility or stock.
Read the advertised-price sourceTirzepatide · Manufacturer direct
Maintenance terms: Self Pay Journey price for 7.5-15 mg with a refill within 45 days; otherwise $499 (7.5 mg) or $699 (10-15 mg).
Needles and syringes cost extra.
Confirm the prescribed dose, supply length, membership or consultation fees, and refill conditions with the provider. A listed offer does not confirm eligibility or stock.
Read the advertised-price sourceTirzepatide · Manufacturer direct
≈ $481.07 per 30 days at this quoted rate
Checked
self-pay cash, higher doses
Maintenance terms: Self Pay Journey price for 7.5-15 mg with a refill within 45 days; otherwise $499 (7.5 mg) or $699 (10-15 mg).
The $449 rate is the Self Pay Journey Program price and holds only with a refill within 45 days; miss the window and the higher doses revert to the regular single-dose vial price of $499 (7.5 mg) or $699 (10 mg, 12.5 mg, and 15 mg). Needles and syringes cost extra.
Confirm the prescribed dose, supply length, membership or consultation fees, and refill conditions with the provider. A listed offer does not confirm eligibility or stock.
Read the advertised-price sourceSemaglutide · Manufacturer direct
≈ $213.21 per 30 days at this quoted rate
Offer through
Checked
first two monthly fills at 0.25 or 0.5 mg for new patients, prescribed by Dec 31, 2026
After the introductory offer: $349 per monthly fill for 0.25, 0.5, or 1 mg; $499 for 2 mg. NovoCare defines one injection fill as a 28-day supply. Eligibility and restrictions apply.
Confirm the prescribed dose, supply length, membership or consultation fees, and refill conditions with the provider. A listed offer does not confirm eligibility or stock.
Read the advertised-price sourceRead prices in context. Compare the same product, dose, and payment terms. A prepaid monthly rate is not a monthly payment. Cost order uses current, recently checked quotes with documented supply periods, converted to 30 days. Other prices are unranked references. Dose changes, introductory terms and added fees affect what you pay.
Missing prices are not estimated. A listed maintenance dose is not a dosing recommendation.
The FDA declared the tirzepatide (December 2024) and semaglutide (February 2025) shortages resolved, ending the exemption that let pharmacies mass-produce compounded copies, and the 503A/503B enforcement-discretion grace periods ended in 2025. The FDA is now actively enforcing (warning letters and takedowns, including a September 2026 warning letter to Empower Pharmacy, a large compounder, over products it called essentially copies of approved semaglutide and tirzepatide), and in 2026 proposed permanently excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list (the public comment period, extended 30 days, closed July 30, 2026; a final decision is pending). Compounded GLP-1s are not FDA-approved and are now generally limited to narrow, patient-specific 503A prescriptions, so broad low-cost availability has largely wound down. They also carry safety risks the branded products do not: FDA adverse-event reports, at least one sterility recall (ProRx, October 2025), and counterfeit product found in the US supply chain, so a low price is not a low-risk signal. Prices and availability below may lag these changes; confirm current terms with the provider.
Some outbound links on GLPcompare are referral links. If you sign up or buy through one, we may earn a commission at no extra cost to you. It never changes the price you pay or the underlying data. Partner status and commission rates contribute to offer and provider value scores and can change their order. Every partner is labeled. Value scores are not medical recommendations; a higher-ranked offer is not necessarily the lowest price or the right product for you.